newsletter is out, page-40

Moosey... Summer ending (did it even begin?) aside, you would think a product that directly addresses the bane of almost every womans existence would have gained more traction by now. If sales are 'subdued' because an awesome product has been replaced with improvements to the already awesome product, this would have been better reflected in the newsletter's wording.

BS is not and has not been flying off the shelves, forgive me for being disappointed in this fact.

So many here harp on about the multi billion dollar pain and diabetes industries... Do you think a product that can get rid of cellulite isn't at least worth in the hundreds of millions? We all agree that partnering with a global pharma and associated royalties would be fantastic, but where's the impetus on them to associate with us if what should be a high demand product is not denting what we know is a massive market full of impostors?

Yes oxy is the main game, but to discount my concerns as an investor who is annoyed we're not 'selling some creams' is ridiculous. Global pharma, whoever they are, probably relies on 'selling creams' and, as it stands, it doesn't look like poh could help them sell any more. This is what it comes down to ultimately. This is why the subdued sales element of the newsletter is so disappointing